SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (3734)2/4/1998 7:35:00 PM
From: Oliver & Co  Read Replies (1) of 6136
 
"Six-Drug Combination Keeps AIDS in Check"
United Press International (02/04/98); Susman, Ed
ÿÿÿÿ Australian doctors reported at the Fifth Conference on
Retroviruses and Opportunistic Infections that a six-drug regimen
including protease inhibitors keeps viral loads of HIV below
detectable levels in patients, even if they had previously failed
other multidrug treatments.ÿ The patients receiving the
therapy--which consists of d4T, ddI, 3TC, nevirapine, nelfinavir,
and saquinavir--had been undergoing AIDS treatment for 10 years;
16 of the 20 patients responded to the new regimen, according to
Sydney physician Dr. Cassy Workman.ÿ Workman expressed surprise
that the new, extensive regimen succeeded, because it contains
only two new drugs, nevirapine and nelfinavir. He said this
offers hope that other AIDS drugs may be "recycled."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News